Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
Authors:
- Francesco de RosaFRFrancesco de Rosa
- Laura RidolfiLaura Ridolfi
- Ruggero RidolfiRRRuggero Ridolfi
- Giorgia GentiliGGGiorgia Gentili
- Linda ValmorriLVLinda Valmorri
- Oriana NanniONOriana Nanni
- Massimiliano PetriniMassimiliano Petrini
- Laura FiammenghiLFLaura Fiammenghi
- Anna Maria GranatoAGAnna Maria Granato
- Valentina AncaraniVAValentina Ancarani
- Elena PancisiEPElena Pancisi
- Valentina SoldatiVSValentina Soldati
Open Access
- 22 July 2014
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 209
Abstract
Vaccination with dendritic cells (DC) loaded with tumor antigens elicits tumor-specific immune responses capable of killing cancer cells without inducing meaningful side-effects. Patients with advanced melanoma enrolled onto our phase II clinical studies have been treated with autologous DC loaded with autologous tumor lysate/homogenate matured with a cytokine cocktail, showing a clinical benefit (PR + SD) in 55.5% of evaluable cases to date. The beneficial effects of the vaccine were mainly restricted to patients who developed vaccine-specific immune response after treatment. However, immunological responses were only induced in about two-thirds of patients, and treatments aimed at improving immunological responsiveness to the vaccine are needed.Keywords
This publication has 53 references indexed in Scilit:
- Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsJournal of Translational Medicine, 2013
- Radiotherapy Effects on Anti-Tumor Immunity: Implications for Cancer TreatmentFrontiers in Oncology, 2013
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Improved Endpoints for Cancer Immunotherapy TrialsJNCI: Journal of the National Cancer Institute, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1βJournal of Biological Chemistry, 2010
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsivenessJournal of Experimental Medicine, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002